Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA OTCMKTS:FSDDF NASDAQ:TCRX NYSEAMERICAN:VNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$9.99+13.8%$5.39$3.92▼$19.15$85.02M-0.31.23 million shs553,098 shsFSDDFFSD Pharma$4.88-2.6%$3.67$3.43▼$68.66$36.99MN/A11,100 shs118,020 shsTCRXTScan Therapeutics$1.13-4.7%$1.12$0.88▼$2.57$64.01M1.06747,839 shs567,732 shsVNRXVolitionRX$2.31+12.5%$3.46$2.01▼$18.80$18.66M1.03450,876 shs168,773 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+5.28%+79.18%+88.82%+81.78%+20.77%FSDDFFSD Pharma0.00%-12.07%+38.44%+16.19%-46.23%TCRXTScan Therapeutics-6.35%-3.28%+12.38%+18.41%-8.17%VNRXVolitionRX-8.89%-15.64%-38.18%-58.16%-79.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$9.99+13.8%$5.39$3.92▼$19.15$85.02M-0.31.23 million shs553,098 shsFSDDFFSD Pharma$4.88-2.6%$3.67$3.43▼$68.66$36.99MN/A11,100 shs118,020 shsTCRXTScan Therapeutics$1.13-4.7%$1.12$0.88▼$2.57$64.01M1.06747,839 shs567,732 shsVNRXVolitionRX$2.31+12.5%$3.46$2.01▼$18.80$18.66M1.03450,876 shs168,773 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+5.28%+79.18%+88.82%+81.78%+20.77%FSDDFFSD Pharma0.00%-12.07%+38.44%+16.19%-46.23%TCRXTScan Therapeutics-6.35%-3.28%+12.38%+18.41%-8.17%VNRXVolitionRX-8.89%-15.64%-38.18%-58.16%-79.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.00Hold$9.50-4.90% DownsideFSDDFFSD Pharma 0.00N/AN/AN/ATCRXTScan Therapeutics 2.33Hold$6.00433.33% UpsideVNRXVolitionRX 2.60Moderate Buy$46.671,923.71% UpsideCurrent Analyst Ratings BreakdownLatest VNRX, TCRX, ATRA, and FSDDF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026ATRAAtara Biotherapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold ➝ Buy$6.00 ➝ $13.005/8/2026ATRAAtara Biotherapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$13.004/21/2026TCRXTScan Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026VNRXVolitionRX CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold4/20/2026VNRXVolitionRX D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/2/2026VNRXVolitionRX HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $20.003/27/2026ATRAAtara Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)3/26/2026VNRXVolitionRX D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.003/18/2026VNRXVolitionRX D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.003/5/2026TCRXTScan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$4.00 ➝ $5.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$120.77M0.70$5.81 per share1.72($5.34) per share-1.87FSDDFFSD Pharma$70K528.43N/AN/AN/A∞TCRXTScan Therapeutics$10.32M6.20N/AN/A$2.16 per share0.52VNRXVolitionRX$1.73M10.78N/AN/A($5.30) per share-0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics$32.69M$3.123.2049.95N/A27.07%-79.12%87.55%5/21/2026 (Estimated)FSDDFFSD Pharma-$17.52M-$1.29N/AN/AN/AN/AN/AN/AN/ATCRXTScan Therapeutics-$129.77M-$0.96N/AN/AN/A-1,360.61%-91.94%-50.15%N/AVNRXVolitionRX-$23.36M-$0.56N/AN/AN/A-1,352.46%N/A-291.77%5/21/2026 (Estimated)Latest VNRX, TCRX, ATRA, and FSDDF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026ATRAAtara Biotherapeutics-$0.3295N/AN/AN/A$2.90 millionN/A5/6/2026Q1 2026TCRXTScan Therapeutics-$0.22-$0.22N/A-$0.22$2.50 million$0.98 million3/16/2026Q4 2025ATRAAtara Biotherapeutics-$0.68-$0.25+$0.43-$0.36$0.70 million$1.60 million3/4/2026Q4 2025TCRXTScan Therapeutics-$0.27-$0.18+$0.09-$0.18$2.44 million$2.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AFSDDFFSD PharmaN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/AVNRXVolitionRXN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A0.820.82FSDDFFSD PharmaN/A1.811.60TCRXTScan Therapeutics0.346.656.65VNRXVolitionRXN/A0.170.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%FSDDFFSD Pharma0.43%TCRXTScan Therapeutics82.83%VNRXVolitionRX8.09%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics41.20%FSDDFFSD PharmaN/ATCRXTScan Therapeutics6.25%VNRXVolitionRX8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3308.51 million5.01 millionNo DataFSDDFFSD Pharma107.58 millionN/ANot OptionableTCRXTScan Therapeutics10056.90 million53.35 millionNot OptionableVNRXVolitionRX808.09 million7.38 millionNot OptionableVNRX, TCRX, ATRA, and FSDDF HeadlinesRecent News About These CompaniesVolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business UpdateMay 11 at 8:19 AM | prnewswire.comVolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in CatsMay 6, 2026 | prnewswire.comVolitionRx Enacts One-for-Twenty Reverse Stock SplitApril 29, 2026 | theglobeandmail.comVolition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis TestingApril 29, 2026 | prnewswire.comVolitionRx (VNRX) price target decreased by 17.48% to 1.73April 28, 2026 | msn.comVNRX: Upcoming Milestones Expected in 2026; Year-End 2025 Results. Special Meeting of Stockholders Approves Reverse-Split. Subsequently, the Board of Directors authorized a 1 ...April 28, 2026 | finance.yahoo.comVolitionRx Announces Acceptance of Compliance Plan by NYSE AmericanApril 23, 2026 | prnewswire.comD Boral Capital downgrades VolitionRx (VNRX)April 21, 2026 | msn.comVolition Launches rNuQ™ Webshop Broadening Product RangeApril 20, 2026 | prnewswire.comVolitionRx Earnings Call: Breakthroughs Amid Funding StrainApril 4, 2026 | tipranks.comVolitionRx Limited (AMEX:VNRX) Q4 2025 earnings call transcriptApril 3, 2026 | msn.comVolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...April 2, 2026 | finance.yahoo.comVolitionRx Limited (VNRX) Q4 2025 Earnings Call TranscriptApril 1, 2026 | seekingalpha.comVolitionRX: Q4 Earnings SnapshotMarch 31, 2026 | ctpost.comCVolitionRX Ltd (VNRX) Q4 2025: Everything You Need to Know Ahead of EarningsMarch 31, 2026 | finance.yahoo.comVolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business UpdateMarch 31, 2026 | prnewswire.comVolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in BelgiumMarch 31, 2026 | prnewswire.comVolition Announces Mayo Clinic Study Demonstrates Nu.Q(R) Concentrations are Elevated in Trauma PatientsMarch 30, 2026 | marketwatch.comVolition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma PatientsMarch 30, 2026 | prnewswire.comVolition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer ConferenceMarch 26, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVNRX, TCRX, ATRA, and FSDDF Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$9.99 +1.21 (+13.78%) As of 11:39 AM EasternAtara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.FSD Pharma OTCMKTS:FSDDF$4.88 -0.13 (-2.59%) As of 05/8/2026FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.TScan Therapeutics NASDAQ:TCRX$1.12 -0.06 (-4.66%) As of 11:55 AM Eastern This is a fair market value price provided by Massive. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.VolitionRX NYSEAMERICAN:VNRX$2.31 +0.26 (+12.49%) As of 11:55 AM Eastern This is a fair market value price provided by Massive. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
